Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Fred Robert Hirsch

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-3858

    Collapse Research 
    Collapse research activities and funding
    U01CA157715     (HIRSCH, FRED R)Jul 9, 2012 - Jun 30, 2017
    NIH/NCI
    Squamous Cell Carcinoma of the Lung: Validation of Molecular Signatures for Progn
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Suda K, Rivard CJ, Mitsudomi T, Hirsch FR. Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Rev Anticancer Ther. 2017 Jul 17; 1-8. PMID: 28701107.
      View in: PubMed
    2. West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2017 Jul 06. PMID: 28801183.
      View in: PubMed
    3. Li X, Cai W, Yang G, Su C, Ren S, Zhao C, Hu R, Chen X, Gao G, Guo Z, Li W, Zhou C, Hirsch FR. Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. J Thorac Oncol. 2017 Jun 15. PMID: 28624467.
      View in: PubMed
    4. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 Aug; 12(8):1183-1209. PMID: 28579481.
      View in: PubMed
    5. Hirsch FR. Programmed death ligand 1 testing: is there one best test? Clin Adv Hematol Oncol. 2017 Jun; 15(6):438-440. PMID: 28749902.
      View in: PubMed
    6. Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H. Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. Clin Lung Cancer. 2017 Apr 26. PMID: 28522158.
      View in: PubMed
    7. Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 2017 Jul; 109:1-8. PMID: 28577937.
      View in: PubMed
    8. He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Med Sci Monit. 2017 Mar 09; 23:1208-1216. PMID: 28275222.
      View in: PubMed
    9. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017 Mar 09. PMID: 28278348.
      View in: PubMed
    10. Suda K, Rozeboom L, Yu H, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS One. 2017; 12(2):e0172209. PMID: 28192473.
      View in: PubMed
    11. Suda K, Murakami I, Yu H, Kim J, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. J Thorac Oncol. 2017 Jun; 12(6):1015-1020. PMID: 28193529.
      View in: PubMed
    12. He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR. LAG-3 Protein Expression in Non-small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017 Jan 26. PMID: 28132868.
      View in: PubMed
    13. Hirsch FR, Zaric B, Rabea A, Thongprasert S, Lertprasertsuke N, Dalurzo ML, Varella-Garcia M. Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries. Am Soc Clin Oncol Educ Book. 2017; 37:403-408. PMID: 28561679.
      View in: PubMed
    14. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017 Feb; 12(2):208-222. PMID: 27913228.
      View in: PubMed
    15. McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT. PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. Lung Cancer. 2017 Jan; 103:52-57. PMID: 28024696.
      View in: PubMed
    16. Yu H, He Y, Rivard C, Chan D, Gao D, Ellison K, Rozeboom L, Suda K, Hirsch F. PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines: Topic: Pathology. J Thorac Oncol. 2016 Nov; 11(11S):S281. PMID: 27969487.
      View in: PubMed
    17. Suda K, Bunn PA, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol. 2017 Jan; 12(1):27-35. PMID: 27642065.
      View in: PubMed
    18. Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. J Thorac Oncol. 2017 Jan; 12(1):110-120. PMID: 27639678.
      View in: PubMed
    19. Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 03; 388(10048):1012-24. PMID: 27598681.
      View in: PubMed
    20. Genova C, Hirsch FR. Clinical potential of necitumumab in non-small cell lung carcinoma. Onco Targets Ther. 2016; 9:5427-37. PMID: 27621656; PMCID: PMC5012835.
    21. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017 Jan 21; 389(10066):299-311. PMID: 27574741.
      View in: PubMed
    22. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. J Thorac Oncol. 2016 Dec; 11(12):2066-2081. PMID: 27575423.
      View in: PubMed
    23. He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016 Sep; 107(9):1193-7. PMID: 27297395.
      View in: PubMed
    24. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 Aug; 11(8):1246-62. PMID: 27453164.
      View in: PubMed
    25. Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol. 2016 Sep; 11(9):1387-96. PMID: 27401214.
      View in: PubMed
    26. Gazdar AF, Hirsch FR, Minna JD. Correction: "From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers". J Thorac Oncol. 2016 Jul; 11(7):e88-9. PMID: 27339412.
      View in: PubMed
    27. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 Sep; 11(9):1411-22. PMID: 27296106.
      View in: PubMed
    28. Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, Mas LA, Arrieta O, Richardet E, Vallejos S C, Wistuba I, Gandara D, Hirsch FR. Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clin Lung Cancer. 2017 Jan; 18(1):e71-e79. PMID: 27426974.
      View in: PubMed
    29. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 Jan; 18(1):43-49. PMID: 27461773.
      View in: PubMed
    30. Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2016 Jun; 11(3):429. PMID: 27056749.
      View in: PubMed
    31. Suda K, Murakami I, Yu H, Ellison K, Shimoji M, Genova C, Rivard CJ, Mitsudomi T, Hirsch FR. Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. J Thorac Oncol. 2016 Oct; 11(10):1711-7. PMID: 27257133.
      View in: PubMed
    32. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 Jul; 11(7):946-63. PMID: 27229180.
      View in: PubMed
    33. Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug; 27(8):1573-9. PMID: 27207107; PMCID: PMC4959928.
    34. Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. cMET Exon 14 Skipping: From the Structure to the Clinic. J Thorac Oncol. 2016 Sep; 11(9):1423-32. PMID: 27223456.
      View in: PubMed
    35. Suda K, Rivard CJ, Mitsudomi T, Hirsch FR. Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter. Cancer Res. 2016 May 15; 76(10):3109-10. PMID: 27197234.
      View in: PubMed
    36. Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016 Jul; 11(7):964-75. PMID: 27117833.
      View in: PubMed
    37. He Y, Sun W, Wang Y, Ren S, Li X, Li J, Rivard CJ, Zhou C, Hirsch FR. Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases. Onco Targets Ther. 2016; 9:2409-14. PMID: 27143936; PMCID: PMC4844452.
    38. Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 May; 11(5):613-38. PMID: 27013409.
      View in: PubMed
    39. Gandara DR, Redman M, Hirsch FR. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. JAMA Oncol. 2016 Mar; 2(3):300-1. PMID: 26720042.
      View in: PubMed
    40. Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74. PMID: 26829312; PMCID: PMC4836290 [Available on 04/01/17].
    41. He Y, Wang Y, Boyle T, Ren S, Chan D, Rivard C, Li X, Li J, Zhou C, Hirsch FR. Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Med Sci Monit. 2016 Jan 26; 22:276-83. PMID: 26811313; PMCID: PMC4734673.
    42. Kerr KM, Hirsch FR. Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? Arch Pathol Lab Med. 2016 Apr; 140(4):326-31. PMID: 26756647.
      View in: PubMed
    43. Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. PMID: 26725184; PMCID: PMC4775366 [Available on 03/01/17].
    44. Gazdar AF, Hirsch FR, Minna JD. From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. J Thorac Oncol. 2016 Mar; 11(3):287-99. PMID: 26723239; PMCID: PMC4809191 [Available on 03/01/17].
    45. Dudnik E, Siegal T, Zach L, Allen AM, Flex D, Yust-Katz S, Limon D, Hirsch FR, Peled N. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. J Clin Neurosci. 2016 Apr; 26:46-9. PMID: 26677785.
      View in: PubMed
    46. Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2015 Dec; 10(4):583-96. PMID: 26004768; PMCID: PMC4661131 [Available on 12/01/16].
    47. Hirsch FR, Bunn PA. Adjuvant TKIs in NSCLC: what can we learn from RADIANT? Nat Rev Clin Oncol. 2015 Dec; 12(12):689-90. PMID: 26552954.
      View in: PubMed
    48. Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan; 9(1):96-104. PMID: 26542061; PMCID: PMC4706769 [Available on 01/01/17].
    49. Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, Chuai S, Fei K, Zhou C, Hirsch FR. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. J Clin Oncol. 2015 Nov 10; 33(32):3701-9. PMID: 26416997; PMCID: PMC4770798.
    50. Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, Zhao M, Li J, Zhang Y, Zhao C, Chen X, Fei K, Zhou C, Hirsch FR. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 2015 Sep 15; 6(27):23582-93. PMID: 26160838; PMCID: PMC4695138.
    51. Soulières D, Hirsch FR, Shepherd FA, Bordogna W, Delmar P, Shames DS, Klughammer B. PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Sep; 10(9):1364-9. PMID: 26291013.
      View in: PubMed
    52. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep; 10(9):1243-60. PMID: 26291008.
      View in: PubMed
    53. Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA, Hirsch FR. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. Oncologist. 2015 Oct; 20(10):1175-81. PMID: 26330460; PMCID: PMC4591939 [Available on 10/01/16].
    54. Rikke BA, Wynes MW, Rozeboom LM, Barón AE, Hirsch FR. Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. Biomark Med. 2015; 9(8):751-61. PMID: 26223535; PMCID: PMC4770796.
    55. Hirsch FR, Herbst RS, Gandara DR. EGFR tyrosine kinase inhibitors in squamous cell lung cancer. Lancet Oncol. 2015 Aug; 16(8):872-3. PMID: 26156654.
      View in: PubMed
    56. Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1083-90. PMID: 26020126; PMCID: PMC4467588.
    57. Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol. 2015 Jul; 10(7):985-9. PMID: 26134220.
      View in: PubMed
    58. Glubb DM, Paré-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge AS, Mirza O, Zhang W, Seiser EL, Rzyman W, Jassem J, Auman T, Hirsch FR, Owzar K, Camps C, Dziadziuszko R, Innocenti F. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1067-75. PMID: 26134224; PMCID: PMC4494119.
    59. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2016 Mar; 38(3):439-47. PMID: 25352401; PMCID: PMC4414661.
    60. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul; 16(7):763-74. PMID: 26045340.
      View in: PubMed
    61. Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Cancer Res. 2015 Oct 01; 21(19):4356-64. PMID: 26015511; PMCID: PMC4592392 [Available on 10/01/16].
    62. Gandara DR, Hammerman PS, Sos ML, Lara PN, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015 May 15; 21(10):2236-43. PMID: 25979930; PMCID: PMC4862209.
    63. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther. 2015 May; 97(5):488-91. PMID: 25676724.
      View in: PubMed
    64. Hornberger J, Hirsch FR, Li Q, Page RD. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. Lung Cancer. 2015 May; 88(2):223-30. PMID: 25804732.
      View in: PubMed
    65. Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. 2015 Jul 01; 121(13):2253-61. PMID: 25740387; PMCID: PMC4560671.
    66. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA, Peled N. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015 Mar; 20(3):316-22. PMID: 25721120; PMCID: PMC4350802.
    67. Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar; 16(3):328-37. PMID: 25701171.
      View in: PubMed
    68. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24. PMID: 25680375; PMCID: PMC4654466.
    69. Hirsch FR. Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease? Transl Lung Cancer Res. 2014 Dec; 3(6):363-4. PMID: 25806320; PMCID: PMC4367675.
    70. Tsao MS, Travis WD, Brambilla E, Nicholson AG, Noguchi M, Hirsch FR. Forty years of the international association for study of lung cancer pathology committee. J Thorac Oncol. 2014 Dec; 9(12):1740-9. PMID: 25393791.
      View in: PubMed
    71. Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015 Mar; 16(2):106-11. PMID: 25467930; PMCID: PMC4770803.
    72. Hirsch FR. International Association for the Study of Lung Cancer (IASLC): celebrating 40 years with scientific and educational achievements! J Thorac Oncol. 2014 Oct; 9(10):1424-5. PMID: 25521396.
      View in: PubMed
    73. Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole DH, Welch JJ, Korn EL, Ullmann CD, Hirsch FR. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. J Thorac Oncol. 2014 Oct; 9(10):1443-8. PMID: 25521397; PMCID: PMC4165474.
    74. Li J, Li X, Ren S, Chen X, Zhang Y, Zhou F, Zhao M, Zhao C, Chen X, Cheng N, Zhao Y, Zhou C, Hirsch FR. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget. 2014 Sep 15; 5(17):7902-16. PMID: 25277203; PMCID: PMC4202169.
    75. Thunnissen E, Noguchi M, Aisner S, Beasley MB, Brambilla E, Chirieac LR, Chung JH, Dacic S, Geisinger KR, Hirsch FR, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Pelosi G, Petersen I, Roggli V, Travis WD, Wistuba I, Yatabe Y, Dziadziuszko R, Witte B, Tsao MS, Nicholson AG. Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol. 2014 Sep; 9(9):1354-62. PMID: 25122431.
      View in: PubMed
    76. Hirsch FR, Bunn PA, Herbst RS. "Companion diagnostics": has their time come and gone? Clin Cancer Res. 2014 Sep 01; 20(17):4422-4. PMID: 25059519; PMCID: PMC4155019.
    77. Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6. PMID: 25042878; PMCID: PMC4169722.
    78. Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE, Hirsch FR. Assessment of folate receptor-a and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients. Clin Lung Cancer. 2014 Sep; 15(5):320-30.e1-3. PMID: 24993594.
      View in: PubMed
    79. Di Maio M, De Marinis F, Hirsch FR, Gridelli C. Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review). Int J Oncol. 2014 Aug; 45(2):509-15. PMID: 24859689.
      View in: PubMed
    80. Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR, Hirsch FR. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014 May; 9(5):631-8. PMID: 24722153; PMCID: PMC4186652.
    81. Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15; 20(12):3299-309. PMID: 24771645; PMCID: PMC4062100.
    82. D'Arcangelo M, Hirsch FR. Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics. 2014; 8:183-92. PMID: 24790411; PMCID: PMC4003149.
    83. Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, Ren R, Zhao C, Li X, Ren S, Zhou C, Hirsch FR. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 2014 Aug 01; 120(15):2299-307. PMID: 24737648.
      View in: PubMed
    84. Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014 Mar; 9(3):e21-3. PMID: 24518095; PMCID: PMC4117236.
    85. Bunn PA, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res. 2014 Apr 01; 20(7):1727-9. PMID: 24583801; PMCID: PMC3998101.
    86. Field JK, Aberle DR, Altorki N, Baldwin DR, Dresler C, Duffy SW, Goldstraw P, Hirsch FR, Pedersen JH, de Koning HJ, Mulshine JL, Sullivan DC, Tsao MS, Travis WD. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. J Thorac Oncol. 2014 Feb; 9(2):141-3. PMID: 24419409.
      View in: PubMed
    87. Hirsch FR, Jotte RM, Berry CA, Mencia WA, Stowell SA, Gardner AJ. Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative. Cancer Control. 2014 Jan; 21(1):90-7. PMID: 24357747.
      View in: PubMed
    88. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014 May; 15(3):173-81. PMID: 24486058.
      View in: PubMed
    89. Hirsch FR, Bunn PA. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan; 2(1):19-21. PMID: 24461890.
      View in: PubMed
    90. Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. J Thorac Oncol. 2013 Dec; 8(12):1492-501. PMID: 24389431; PMCID: PMC3934792.
    91. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. PMID: 24189513; PMCID: PMC4072123.
    92. Peled N, Zach L, Liran O, Ilouze M, Bunn PA, Hirsch FR. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol. 2013 Dec; 8(12):e112-3. PMID: 24389447.
      View in: PubMed
    93. Göke F, Göke A, von Mässenhausen A, Franzen A, Sharma R, Kirsten R, Böhm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W, Heasley L, Buettner R, Perner S. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion. 2013; 88(3):172-81. PMID: 24135816; PMCID: PMC4186657.
    94. Hirsch FR. Squamous cell lung cancer: where do we stand and where are we going? Oncology (Williston Park). 2013 Sep; 27(9):914-5. PMID: 24282990.
      View in: PubMed
    95. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013; 3:219. PMID: 24010120; PMCID: PMC3755267.
    96. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. PMID: 23910067; PMCID: PMC4122504.
    97. Hirsch FR, Gandara DR. FASTACT-2: but don't act too fast. Lancet Oncol. 2013 Jul; 14(8):684-5. PMID: 23782815.
      View in: PubMed
    98. Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr). 2013 Jul; 36(4):277-88. PMID: 23619944; PMCID: PMC4186686.
    99. Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013 Jun 01; 73(11):3381-92. PMID: 23576557; PMCID: PMC3674118.
    100. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013 Aug; 7(4):776-90. PMID: 23607916; PMCID: PMC3760013.
    101. D'Arcangelo M, Wynes MW, Hirsch FR. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. Curr Opin Oncol. 2013 Mar; 25(2):121-9. PMID: 23385859.
      View in: PubMed
    102. Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013 Mar; 8(3):373-84. PMID: 23370315.
      View in: PubMed
    103. Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA, Hirsch FR, Haick H. Volatile fingerprints of cancer specific genetic mutations. Nanomedicine. 2013 Aug; 9(6):758-66. PMID: 23428987; PMCID: PMC4186653.
    104. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul; 14(4):351-5. PMID: 23415808; PMCID: PMC4567037.
    105. Hirsch FR. The TOPICAL study should be more topical! Transl Lung Cancer Res. 2013 Feb; 2(1):62-3. PMID: 25806207; PMCID: PMC4367651.
    106. Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol. 2013 Jan; 8(1):19-30. PMID: 23242435; PMCID: PMC3645936.
    107. Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila). 2013 Feb; 6(2):100-8. PMID: 23268837; PMCID: PMC4159305.
    108. Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013 Apr; 49(6):1161-8. PMID: 23265711.
      View in: PubMed
    109. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol. 2012 Dec; 7(12):e36-8. PMID: 23154564.
      View in: PubMed
    110. Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012 Oct; 7(10):1528-33. PMID: 22929969; PMCID: PMC3444531.
    111. Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2012 Sep; 7(9):1440-8. PMID: 22895141; PMCID: PMC3645940.
    112. Peled N, Palmer G, Hirsch FR, Wynes MW, Ilouze M, Varella-Garcia M, Soussan-Gutman L, Otto GA, Stephens PJ, Ross JS, Cronin MT, Lipson D, Miller VA. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012 Sep; 7(9):e14-6. PMID: 22895149; PMCID: PMC3645938.
    113. Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Welter S, Stamatis G, Hirsch FR, Schuler M, Eberhardt WE, Wohlschlaeger J. ßV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. Br J Cancer. 2012 Aug 21; 107(5):823-30. PMID: 22836512; PMCID: PMC3425975.
    114. Ekman S, Wynes MW, Hirsch FR. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol. 2012 Jun; 7(6):947-53. PMID: 22588151.
      View in: PubMed
    115. Wynes MW, Konopa K, Singh S, Reyna-Asuncion B, Ranger-Moore J, Sternau A, Christoph DC, Dziadziuszko R, Jassem J, Hirsch FR. Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. J Thorac Oncol. 2012 Jun; 7(6):982-92. PMID: 22551903; PMCID: PMC3645942.
    116. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res. 2012 Aug 01; 18(15):4004-12. PMID: 22592956; PMCID: PMC3409929.
    117. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012 Jun 20; 30(18):2248-55. PMID: 22508830; PMCID: PMC4798782.
    118. Christoph DC, Hoffmann AC, Gauler TC, Asuncion BR, Loewendick H, Peglow A, Hassan B, Tran C, Wynes MW, Schuler M, Eberhard WE, Hirsch FR. Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. J Thorac Oncol. 2012 Apr; 7(4):766-7. PMID: 22425929; PMCID: PMC3358927.
    119. Hirsch FR, Bunn PA. A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. Lancet Oncol. 2012 May; 13(5):442-3. PMID: 22452893.
      View in: PubMed
    120. Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):419-26. PMID: 22237261; PMCID: PMC3358820.
    121. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, Rzyman W, Szostakiewicz B, Jassem J, Hirsch FR. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):340-7. PMID: 22237262; PMCID: PMC3358920.
    122. Hirsch FR, Herbst RS. EGFR expression and the flexibility of FLEX. Lancet Oncol. 2012 Jan; 13(1):3-5. PMID: 22056020.
      View in: PubMed
    123. Barash O, Peled N, Tisch U, Bunn PA, Hirsch FR, Haick H. Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine. 2012 Jul; 8(5):580-9. PMID: 22033081; PMCID: PMC4745892.
    124. Mascaux C, Wynes MW, Kato Y, Tran C, Asuncion BR, Zhao JM, Gustavson M, Ranger-Moore J, Gaire F, Matsubayashi J, Nagao T, Yoshida K, Ohira T, Ikeda N, Hirsch FR. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res. 2011 Dec 15; 17(24):7796-807. PMID: 21994417; PMCID: PMC3266947.
    125. Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold Ch, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Ann Oncol. 2012 May; 23(5):1223-9. PMID: 21940784.
      View in: PubMed
    126. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Yang PC, Gould M. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011 Sep; 8(5):381-5. PMID: 21926387.
      View in: PubMed
    127. Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E, Hirsch FR, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer. 2011 Sep 06; 105(6):814-23. PMID: 21847116; PMCID: PMC3171012.
    128. Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Camidge R, Camidge DR. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Sep 10; 29(26):3567-73. PMID: 21825259; PMCID: PMC3179254.
    129. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67. PMID: 21712447; PMCID: PMC3156871.
    130. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA, Geraci MW, Miller YE. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila). 2011 Jun; 4(6):793-802. PMID: 21636546; PMCID: PMC3251330.
    131. Camidge DR, Hirsch FR, Varella-Garcia M, Franklin WA. Finding ALK-positive lung cancer: what are we really looking for? J Thorac Oncol. 2011 Mar; 6(3):411-3. PMID: 21317739.
      View in: PubMed
    132. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb; 6(2):244-85. PMID: 21252716; PMCID: PMC4513953.
    133. Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2011 Jan; 6(1):21-7. PMID: 21107285; PMCID: PMC3359090.
    134. Badzio A, Wynes MW, Dziadziuszko R, Merrick DT, Pardo M, Rzyman W, Kowalczyk A, Singh S, Ranger-Moore J, Manriquez G, Gaire F, Jassem J, Hirsch FR. Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1905-11. PMID: 21124078; PMCID: PMC3356161.
    135. Hirsch FR. November--lung cancer awareness month! J Thorac Oncol. 2010 Nov; 5(11):1719-20. PMID: 20975370.
      View in: PubMed
    136. Hirsch FR, Wynes MW, Gandara DR, Bunn PA. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010 Oct 15; 16(20):4909-11. PMID: 20926402.
      View in: PubMed
    137. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 01; 28(31):4747-54. PMID: 20921467; PMCID: PMC3020704.
    138. Patz EF, Caporaso NE, Dubinett SM, Massion PP, Hirsch FR, Minna JD, Gatsonis C, Duan F, Adams A, Apgar C, Medina RM, Aberle DR. National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers. J Thorac Oncol. 2010 Oct; 5(10):1502-6. PMID: 20871260; PMCID: PMC2963472.
    139. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010 Oct; 5(10):1706-13. PMID: 20871269.
      View in: PubMed
    140. Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol. 2010 Oct; 5(10):1551-8. PMID: 20697298; PMCID: PMC2946481.
    141. Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR. Early detection and screening of lung cancer. Expert Rev Mol Diagn. 2010 Sep; 10(6):799-815. PMID: 20843203.
      View in: PubMed
    142. Bunn PA, Hirsch FR, Doebele RC, Camidge DR, Varella-Garcia M, Franklin W. Biomarkers are here to stay for clinical research and standard care. J Thorac Oncol. 2010 Aug; 5(8):1113-5. PMID: 20661083.
      View in: PubMed
    143. Hirsch FR, Mok TS, Borges V, Bunn PA. Molecularly targeted therapy: when to stop and when to continue? Lancet Oncol. 2010 Aug; 11(8):709-11. PMID: 20570560.
      View in: PubMed
    144. Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res. 2010 Jun 15; 16(12):3193-204. PMID: 20530704; PMCID: PMC2889230.
    145. Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, Garg K, Hirsch FR, Noguchi M, Powell CA, Rusch VW, Scagliotti G, Yatabe Y. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010 Apr; 5(4):411-4. PMID: 20357614.
      View in: PubMed
    146. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010 May 01; 28(13):2174-80. PMID: 20351332; PMCID: PMC2860435.
    147. Varella-Garcia M, Schulte AP, Wolf HJ, Feser WJ, Zeng C, Braudrick S, Yin X, Hirsch FR, Kennedy TC, Keith RL, Barón AE, Belinsky SA, Miller YE, Byers T, Franklin WA. The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence. Cancer Prev Res (Phila). 2010 Apr; 3(4):447-53. PMID: 20332298; PMCID: PMC2939746.
    148. Barash O, Peled N, Hirsch FR, Haick H. Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles. Small. 2009 Nov; 5(22):2618-24. PMID: 19705367; PMCID: PMC3368377.
    149. Peled N, Yoshida K, Wynes MW, Hirsch FR. Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):137-44. PMID: 21789118; PMCID: PMC3125998.
    150. Leidner RS, Fu P, Clifford B, Hamdan A, Jin C, Eisenberg R, Boggon TJ, Skokan M, Franklin WA, Cappuzzo F, Hirsch FR, Varella-Garcia M, Halmos B. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol. 2009 Nov 20; 27(33):5620-6. PMID: 19786660; PMCID: PMC3329938.
    151. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, Schwartz AG, Vahakangas KH, Samet JM. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 2009 Sep 15; 15(18):5646-61. PMID: 19755392; PMCID: PMC2950319.
    152. Hirsch FR. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. Oncogene. 2009 Aug; 28 Suppl 1:S1-3. PMID: 19680291.
      View in: PubMed
    153. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 2009 Aug; 28 Suppl 1:S32-7. PMID: 19680294.
      View in: PubMed
    154. Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer. 2009 Jul; 10(4):262-72. PMID: 19632946.
      View in: PubMed
    155. Massion PP, Zou Y, Uner H, Kiatsimkul P, Wolf HJ, Baron AE, Byers T, Jonsson S, Lam S, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M. Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer. PLoS One. 2009 Jun 09; 4(6):e5611. PMID: 19547694; PMCID: PMC2699220.
    156. Herbst RS, Hirsch FR. Patient selection criteria and the FLEX Study. Lancet. 2009 May 02; 373(9674):1497-8. PMID: 19410696.
      View in: PubMed
    157. Hirsch FR, Bunn PA. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009 May; 10(5):432-3. PMID: 19410185.
      View in: PubMed
    158. Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila). 2009 May; 2(5):440-9. PMID: 19401528; PMCID: PMC3103211.
    159. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10; 27(11):1864-71. PMID: 19289630.
      View in: PubMed
    160. Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B, Hirsch FR, Varella-Garcia M, Duffield E, Ataman OU, Zarenda M, Armour AA. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol. 2009 May 01; 27(13):2253-60. PMID: 19289623; PMCID: PMC4886538.
    161. Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA, Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol. 2009 Mar; 4(3):318-25. PMID: 19247083; PMCID: PMC3379811.
    162. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J. 2009 Mar-Apr; 15(2):110-3. PMID: 19390304.
      View in: PubMed
    163. Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA, Hirsch FR. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol. 2009 Apr; 20(4):689-95. PMID: 19150934; PMCID: PMC2722370.
    164. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009 Mar 01; 27(7):1130-6. PMID: 19124802.
      View in: PubMed
    165. Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009 Jan; 1(1):19-25. PMID: 20635969.
      View in: PubMed
    166. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008 Dec; 3(12):1468-81. PMID: 19057275.
      View in: PubMed
    167. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, Lin M, O'Neill V, Bunn PA. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008 Oct 01; 14(19):6317-23. PMID: 18829515; PMCID: PMC3368373.
    168. Crinò L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4253-60. PMID: 18779612.
      View in: PubMed
    169. Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008 Sep; 3(9):1026-31. PMID: 18758306; PMCID: PMC3523698.
    170. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol. 2008 Aug; 3(8):815-8. PMID: 18670298.
      View in: PubMed
    171. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7. PMID: 18612151; PMCID: PMC3368372.
    172. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42. PMID: 18520298.
      View in: PubMed
    173. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S107-12. PMID: 18520291.
      View in: PubMed
    174. Varella-Garcia M, Ladanyi M, Kris MG, Li A, Chitale DA, Rekhtman N, Riely GJ, Miller VA, Hirsch FR, Zakowski MF. Comparison of CISH and FISH for detection of EGFR copy number in lung adenocarcinoma and correlation with EGFR and KRAS mutation status and EGFR immunoreactivity. J Clin Oncol. 2008 May 20; 26(15_suppl):22105. PMID: 27950806.
      View in: PubMed
    175. Olsen CC, Paulus R, Komaki R, Varella-Garcia M, Dziadziuszko R, Curran WJ, Robert F, Choy H, Blumenschein GR, Hirsch FR. RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)-Association between EGFR gene copy number and patients' outcome. J Clin Oncol. 2008 May 20; 26(15_suppl):7607. PMID: 27948673.
      View in: PubMed
    176. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res. 2008 Apr 15; 68(8):2841-9. PMID: 18413752.
      View in: PubMed
    177. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA, Franklin WA. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer. 2008 Mar 01; 112(5):1114-21. PMID: 18219661; PMCID: PMC3355966.
    178. Dziadziuszko R, Hirsch FR. Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective. Clin Lung Cancer. 2008 Mar; 9(2):78-84. PMID: 18501093.
      View in: PubMed
    179. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008 Jun; 19(6):1053-9. PMID: 18304967.
      View in: PubMed
    180. Byers T, Wolf HJ, Franklin WA, Braudrick S, Merrick DT, Shroyer KR, Hirsch FR, Zeng C, Barón AE, Bunn PA, Miller YE, Kennedy TC. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):158-62. PMID: 18199720.
      View in: PubMed
    181. Jonsson S, Varella-Garcia M, Miller YE, Wolf HJ, Byers T, Braudrick S, Kiatsimkul P, Lewis M, Kennedy TC, Keith RL, Bjornsson J, McWilliams A, Lam S, Hirsch FR, Franklin WA. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am J Respir Crit Care Med. 2008 Feb 01; 177(3):342-7. PMID: 17989344; PMCID: PMC2218849.
    182. Miller YE, Blatchford P, Hyun DS, Keith RL, Kennedy TC, Wolf H, Byers T, Bunn PA, Lewis MT, Franklin WA, Hirsch FR, Kittelson J. Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2425-31. PMID: 18006932.
      View in: PubMed
    183. Hirsch FR. EGFR inhibitors in the treatment of lung cancer. Onkologie. 2007 Oct; 30(10):476. PMID: 17890885.
      View in: PubMed
    184. Varella-Garcia M, Chen L, Powell RL, Hirsch FR, Kennedy TC, Keith R, Miller YE, Mitchell JD, Franklin WA. Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. Am J Respir Crit Care Med. 2007 Sep 01; 176(5):505-12. PMID: 17600274; PMCID: PMC1976541.
    185. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007 Jun 06; 99(11):838-46. PMID: 17551144.
      View in: PubMed
    186. Cappuzzo F, Ligorio C, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Hirsch FR, Crino L, Varella-Garcia M. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007 May; 2(5):423-9. PMID: 17473658.
      View in: PubMed
    187. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007 Apr; 18(4):752-60. PMID: 17317677.
      View in: PubMed
    188. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. PMID: 17382026.
      View in: PubMed
    189. Dziadziuszko R, Siemiatkowska A, Limon J, Rzyman W, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. J Thorac Oncol. 2007 Jan; 2(1):91-2. PMID: 17410018.
      View in: PubMed
    190. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25. PMID: 17145836.
      View in: PubMed
    191. Dziadziuszko R, Holm B, Skov BG, Osterlind K, Sellers MV, Franklin WA, Bunn PA, Varella-Garcia M, Hirsch FR. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol. 2007 Mar; 18(3):447-52. PMID: 17082511.
      View in: PubMed
    192. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 01; 24(31):5034-42. PMID: 17075123.
      View in: PubMed
    193. Mulshine JL, Avila RS, Hirsch FR, Yankelevitz D. Developing CT image-processing tools to accelerate progress in lung cancer drug development. Oncology (Williston Park). 2006 Nov; 20(12):1606, 1608-10, 1614 passim. PMID: 17153911.
      View in: PubMed
    194. Crawford J, Kosmidis PA, Hirsch FR, Langer CJ. Targeting anemia in patients with lung cancer. J Thorac Oncol. 2006 Sep; 1(7):716-25. PMID: 17409943.
      View in: PubMed
    195. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, Cmelak A, Levy S, Yarbrough WG, Slebos RJ, Hirsch FR. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006 Sep 01; 24(25):4170-6. PMID: 16943533.
      View in: PubMed
    196. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006 Aug; 4(8):521-8. PMID: 16877703.
      View in: PubMed
    197. Dziadziuszko R, Hirsch FR, Varella-Garcia M, Bunn PA. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how? Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4409s-4415s. PMID: 16857819.
      View in: PubMed
    198. Hirsch FR. K-ras mutations in lung cancer: the "mysterious mutation". Clin Lung Cancer. 2006 Jul; 8(1):11-2. PMID: 16870039.
      View in: PubMed
    199. Bunn PA, Dziadziuszko R, Varella-Garcia M, Franklin WA, Witta SE, Kelly K, Hirsch FR. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res. 2006 Jun 15; 12(12):3652-6. PMID: 16778092.
      View in: PubMed
    200. Hirsch FR. EGFR: a prognostic and/or a predictive marker? J Thorac Oncol. 2006 Jun; 1(5):395-7. PMID: 17409888.
      View in: PubMed
    201. Field JK, Smith RA, Duffy SW, Berg CD, van Klaveren R, Henschke CI, Carbone D, Postmus PE, Paci E, Hirsch FR, Mulshine JL. The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. J Thorac Oncol. 2006 Jun; 1(5):497-8. PMID: 17409906.
      View in: PubMed
    202. Dziadziuszko R, Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA, Varella-Garcia M, Danenberg KD, Hirsch FR. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006 May 15; 12(10):3078-84. PMID: 16707605.
      View in: PubMed
    203. Garfield DH, Cadranel JL, Wislez M, Franklin WA, Hirsch FR. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol. 2006 May; 1(4):344-59. PMID: 17409882.
      View in: PubMed
    204. Miller YE, Vu KO, Kennedy TC, Hirsch FR, Petty TL, Bunn PA, Keith RL, Franklin WA, Wolf HJ, Prindiville S, Byers T. Lack of association between sputum atypia and chronic obstructive pulmonary disease mortality. J Thorac Oncol. 2006 May; 1(4):302-7. PMID: 17409874.
      View in: PubMed
    205. Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2006 Jul; 17(7):1120-7. PMID: 16600976.
      View in: PubMed
    206. Merrick DT, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith RL, Kennedy TC, Miller YE, Franklin WA, Hirsch FR. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2281-8. PMID: 16609045.
      View in: PubMed
    207. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006 Mar 15; 66(6):3338-44. PMID: 16540689.
      View in: PubMed
    208. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006 Jan 15; 66(2):944-50. PMID: 16424029.
      View in: PubMed
    209. Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA, Hirsch FR, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer. 2005 Dec 12; 93(12):1334-40. PMID: 16288303; PMCID: PMC2361531.
    210. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005 Dec; 167(6):1763-75. PMID: 16314486; PMCID: PMC1613183.
    211. Hirsch FR. Does lung cancer screening motivate smoking cessation? Nat Clin Pract Oncol. 2005 Dec; 2(12):616-7. PMID: 16341116.
      View in: PubMed
    212. Hirsch FR, Bunn PA. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol. 2005 Dec 20; 23(36):9044-7. PMID: 16301593.
      View in: PubMed
    213. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005 Aug 01; 23(22):5007-18. PMID: 16051952.
      View in: PubMed
    214. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45. PMID: 15998906.
      View in: PubMed
    215. Cappuzzo F, Toschi L, Shigematsu H, Rossi E, Ceresoli G, Crino L, Bunn PA, Gazdar AF, Hirsch FR, Varella-Garcia M. HER2 and HER3 genomic gain increases sensitivity to gefitinib in epidermal growth factor receptor positive advanced non-small cell lung cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):3021. PMID: 27945773.
      View in: PubMed
    216. Gumerlock PH, Holland WS, Chen H, Franklin WA, Hirsch FR, Mack PC, Davies AM, McCoy J, West HJ, Gandara DR. Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib. J Clin Oncol. 2005 Jun; 23(16_suppl):7008. PMID: 27943798.
      View in: PubMed
    217. Hirsch FR, Gandara DR, McCoy J, Crowley J, West HJ, Gummerlock PH, Bunn PA, Franklin WA, Varella-Garcia M. Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126). J Clin Oncol. 2005 Jun; 23(16_suppl):7030. PMID: 27944483.
      View in: PubMed
    218. Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J Clin Oncol. 2005 May 10; 23(14):3186-97. PMID: 15886305.
      View in: PubMed
    219. Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol. 2005 May 10; 23(14):3288-93. PMID: 15886316.
      View in: PubMed
    220. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005 May 04; 97(9):643-55. PMID: 15870435.
      View in: PubMed
    221. Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA, Miller YE. High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia. Lung Cancer. 2005 Aug; 49(2):187-91. PMID: 16022912.
      View in: PubMed
    222. Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol. 2005 Mar; 17(2):118-22. PMID: 15725915.
      View in: PubMed
    223. Kennedy TC, Hirsch FR. Using molecular markers in sputum for the early detection of lung cancer: a review. Lung Cancer. 2004 Aug; 45 Suppl 2:S21-7. PMID: 15552778.
      View in: PubMed
    224. Chanin TD, Merrick DT, Franklin WA, Hirsch FR. Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. Curr Opin Pulm Med. 2004 Jul; 10(4):242-7. PMID: 15220746.
      View in: PubMed
    225. Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4205s-4209s. PMID: 15217959.
      View in: PubMed
    226. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4227s-4232s. PMID: 15217963.
      View in: PubMed
    227. Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA, Miller YE. High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum. Chest. 2004 May; 125(5 Suppl):109S. PMID: 15136448.
      View in: PubMed
    228. Vistisen K, Loft S, Olsen JH, Vallentin S, Ottesen S, Hirsch FR, Poulsen HE. Low CYP1A2 activity associated with testicular cancer. Carcinogenesis. 2004 Jun; 25(6):923-9. PMID: 14976127.
      View in: PubMed
    229. Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):75-82. PMID: 14981584.
      View in: PubMed
    230. Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA. Chemoprevention of lung cancer--from biology to clinical reality. Ann Oncol. 2004 Feb; 15(2):185-96. PMID: 14760107.
      View in: PubMed
    231. Varella-Garcia M, Kittelson J, Schulte AP, Vu KO, Wolf HJ, Zeng C, Hirsch FR, Byers T, Kennedy T, Miller YE, Keith RL, Franklin WA. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. Cancer Detect Prev. 2004; 28(4):244-51. PMID: 15350627.
      View in: PubMed
    232. van Zandwijk N, Hirsch FR. Chemoprevention of lung cancer: current status and future prospects. Lung Cancer. 2003 Dec; 42 Suppl 1:S71-9. PMID: 14611918.
      View in: PubMed
    233. Prindiville SA, Byers T, Hirsch FR, Franklin WA, Miller YE, Vu KO, Wolf HJ, Barón AE, Shroyer KR, Zeng C, Kennedy TC, Bunn PA. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev. 2003 Oct; 12(10):987-93. PMID: 14578133.
      View in: PubMed
    234. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003 Oct 15; 21(20):3798-807. PMID: 12953099.
      View in: PubMed
    235. Jablons DM, Cheng SJ, Carolyn Clary-Macy RN, Hirsch FR. 1st International Lung Cancer Conference in Beijing, October 27-30, 2002. Lung Cancer. 2003 Aug; 41(2):237-44. PMID: 12871790.
      View in: PubMed
    236. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. 2003 Aug; 41 Suppl 1:S29-42. PMID: 12867060.
      View in: PubMed
    237. Mulshine JL, Hirsch FR. Lung cancer chemoprevention: moving from concept to a reality. Lung Cancer. 2003 Aug; 41 Suppl 1:S163-74. PMID: 12867075.
      View in: PubMed
    238. Hirsch FR, Bunn PA, Johnson DH, Giaccone G, Rosell R. Lung cancer. Introduction. Lung Cancer. 2003 Aug; 41 Suppl 1:S1. PMID: 12867055.
      View in: PubMed
    239. Langer CJ, Hirsch FR, Cortés-Funes H, Sawyer ST, Thatcher N. Targeted molecular mechanisms of epoetin alfa. Lung Cancer. 2003 Aug; 41 Suppl 1:S133-45. PMID: 12867072.
      View in: PubMed
    240. Romeo MS, Sokolova IA, Morrison LE, Zeng C, Barón AE, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M. Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn. 2003 May; 5(2):103-12. PMID: 12707375; PMCID: PMC1907319.
    241. Mulshine JL, Smith RA, Field JK, Hirsch FR. Tobacco money: up in smoke? Lancet. 2002 Dec 14; 360(9349):1979-80; author reply 1981. PMID: 12493299.
      View in: PubMed
    242. Hirsch FR, Fischer JR, Niklinski J, Zöchbaüer-Müller S. Future developments in the treatment of lung cancer. Lung Cancer. 2002 Dec; 38 Suppl 3:S81-5. PMID: 12468154.
      View in: PubMed
    243. Niklinski J, Hirsch FR. Molecular approaches to lung cancer evaluation. Lung Cancer. 2002 Dec; 38 Suppl 3:S9-17. PMID: 12468138.
      View in: PubMed
    244. van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR. Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer. 2002 Dec; 38(3):243-52. PMID: 12445745.
      View in: PubMed
    245. Hirsch FR, Bunn PA, Dmitrovsky E, Field JK, Franklin WA, Greenberg RE, Hansen HH, Henschke CI, Rigas JR, Smith RA, Toennesen P, Mulshine JL. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001. Lung Cancer. 2002 Sep; 37(3):325-44. PMID: 12234703.
      View in: PubMed
    246. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer. 2002 Aug; 37(2):127-35. PMID: 12140134.
      View in: PubMed
    247. Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 2002 Jul 15; 62(14):3971-9. PMID: 12124329.
      View in: PubMed
    248. Hirsch FR, Merrick DT, Franklin WA. Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J. 2002 Jun; 19(6):1151-8. PMID: 12108871.
      View in: PubMed
    249. Hirsch FR, Franklin WA, Bunn PA. Expression of target molecules in lung cancer: challenge for a new treatment paradigm. Semin Oncol. 2002 Jun; 29(3 Suppl 9):2-8. PMID: 12094332.
      View in: PubMed
    250. Hirsch FR, Franklin WA, Bunn PA. What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? Lung Cancer. 2002 Jun; 36(3):263-4. PMID: 12009235.
      View in: PubMed
    251. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. 2002 May 15; 20(10):2417-28. PMID: 12011119.
      View in: PubMed
    252. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002 May 06; 86(9):1449-56. PMID: 11986780; PMCID: PMC2375387.
    253. Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clin Breast Cancer. 2002 May; 3 Suppl 1:12-6. PMID: 12057039.
      View in: PubMed
    254. Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer. 2002 May; 36(2):115-24. PMID: 11955645.
      View in: PubMed
    255. van Zandwijk N, Hirsch FR. Chemoprevention strategies for non-small cell lung cancer. Curr Opin Oncol. 2002 Mar; 14(2):185-90. PMID: 11880709.
      View in: PubMed
    256. Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE, Vejborg IM, Mouridsen H, Lynge E. [Mammographic screening in the county of Copenhagen. Clinical consequences of the first three screening rounds]. Ugeskr Laeger. 2002 Feb 18; 164(8):1036-40. PMID: 11894704.
      View in: PubMed
    257. Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE, Vejborg IM, Mouridsen H, Lynge E. [Mammography screening in the county of Copenhagen. Results of the first three screening rounds]. Ugeskr Laeger. 2002 Feb 18; 164(8):1048-52. PMID: 11894707.
      View in: PubMed
    258. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol. 2002 Feb; 29(1 Suppl 4):51-8. PMID: 11894014.
      View in: PubMed
    259. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002 Feb; 29(1 Suppl 4):3-14. PMID: 11894009.
      View in: PubMed
    260. Bunn PA, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001 Oct; 7(10):3239-50. PMID: 11595720.
      View in: PubMed
    261. Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, Bunn PA, Kennedy TC. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst. 2001 Sep 19; 93(18):1385-91. PMID: 11562389.
      View in: PubMed
    262. Hirsch FR, Hansen HH. [New techniques for early diagnosis of lung cancer]. Ugeskr Laeger. 2001 Aug 13; 163(33):4321-3. PMID: 11521560.
      View in: PubMed
    263. Bremnes RM, Hirsch FR. [Lung cancer screening--what now?]. Tidsskr Nor Laegeforen. 2001 May 20; 121(13):1600-4. PMID: 11446046.
      View in: PubMed
    264. Hirsch FR, Osterlind K, Jeppesen N, Dombernowsky P, Ingeberg S, Sorensen PG, Kristensen C, Hansen HH. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. Ann Oncol. 2001 May; 12(5):647-53. PMID: 11432623.
      View in: PubMed
    265. Byers T, Hirsch FR. Computed tomography screening for lung cancer: what should we recommend? Cancer Pract. 2001 Mar-Apr; 9(2):97-9. PMID: 11879285.
      View in: PubMed
    266. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res. 2001 Jan; 7(1):5-22. PMID: 11205917.
      View in: PubMed
    267. Kennedy TC, Lam S, Hirsch FR. Review of recent advances in fluorescence bronchoscopy in early localization of central airway lung cancer. Oncologist. 2001; 6(3):257-62. PMID: 11423672.
      View in: PubMed
    268. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000 Sep; 18(17):3084-92. PMID: 10963636.
      View in: PubMed
    269. Sorensen M, Jensen PB, Herrstedt J, Hirsch FR, Hansen HH. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Ann Oncol. 2000 Jul; 11(7):829-35. PMID: 10997810.
      View in: PubMed
    270. Skuladottir H, Olsen JH, Hirsch FR. Incidence of lung cancer in Denmark: historical and actual status. Lung Cancer. 2000 Feb; 27(2):107-18. PMID: 10688493.
      View in: PubMed
    271. Skuladottir H, Hirsch FR, Olsen JH. [Primary lung cancer in Denmark. Historical and current developmental tendencies]. Ugeskr Laeger. 1999 Nov 08; 161(45):6179-84. PMID: 10603754.
      View in: PubMed
    272. Hirsch FR. [Early diagnosis of cancer]. Ugeskr Laeger. 1999 Jun 28; 161(26):3979. PMID: 10402929.
      View in: PubMed
    273. Lassen UN, Osterlind K, Hirsch FR, Bergman B, Dombernowsky P, Hansen HH. Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer. 1999 Feb; 79(3-4):515-9. PMID: 10027322; PMCID: PMC2362437.
    274. Sculier JP, Joss RA, Schefer H, Hirsch FR, Hansen HH. Should maintenance chemotherapy be used to treat small cell lung cancer? Eur J Cancer. 1998 Jul; 34(8):1148-55. PMID: 9849472.
      View in: PubMed
    275. Lassen UN, Hirsch FR, Osterlind K, Bergman B, Dombernowsky P. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung Cancer. 1998 Jun; 20(3):151-60. PMID: 9733049.
      View in: PubMed
    276. Hirsch FR, Brambilla E, Gray N, Gritz E, Kelloff GJ, Linnoila RI, Pastorino U, Mulshine JL. Prevention and early detection of lung cancer-clinical aspects. Lung Cancer. 1997 May; 17(1):163-74. PMID: 9194035.
      View in: PubMed
    277. Jørgensen LG, Løber J, Carlsen NL, Momsen G, Hirsch FR. Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. Clin Chim Acta. 1996 May 30; 249(1-2):77-91. PMID: 8737594.
      View in: PubMed
    278. Lassen U, Kristjansen PE, Osterlind K, Bergman B, Sigsgaard TC, Hirsch FR, Hansen M, Dombernowsky P, Hansen HH. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol. 1996 Apr; 7(4):365-71. PMID: 8805928.
      View in: PubMed
    279. Hirsch FR, Mouridsen HT, Hansen OP, Jørgensen T, Blichert-Toft M, Rank FE, Jensen MB. [Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen]. Ugeskr Laeger. 1996 Feb 26; 158(9):1218-21. PMID: 8644426.
      View in: PubMed
    280. Jørgensen T, Jensen LB, Duun S, Hirsch FR, Mouridsen HT, Blichert-Toft M, Rank FE, Christensen LH, Hansen AG, Nissen FH, et al. [Mammographic screening in the municipality of Copenhagen. Results of the first screening round]. Ugeskr Laeger. 1996 Feb 26; 158(9):1212-7. PMID: 8644425.
      View in: PubMed
    281. Langer SW, Krasnik M, Hirsch FR, Dombernowsky P. [Male breast cancer. A review]. Ugeskr Laeger. 1996 Jan 01; 158(1):37-40. PMID: 8560622.
      View in: PubMed
    282. Hoffmann L, Möller P, Pedersen-Bjergaard J, Waage A, Pedersen M, Hirsch FR. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann Oncol. 1995 Oct; 6(8):781-8. PMID: 8589015.
      View in: PubMed
    283. Senderovitz T, Skov BG, Hirsch FR. Neuroendocrine characteristics in malignant lung tumors: implications for diagnosis, treatment, and prognosis. Cancer Treat Res. 1995; 72:143-54. PMID: 7702985.
      View in: PubMed
    284. Skov BG, Braendstrup O, Hirsch FR, Lauritzen AF, Nielsen HW, Skov T. Are pathologists biased by clinical information?: A blinded cross-over study of the histopathological diagnosis of mesothelial tumours versus pulmonary adenocarcinoma. Lung Cancer. 1994 Dec; 11(5-6):365-72. PMID: 7704493.
      View in: PubMed
    285. Skov BG, Lauritzen AF, Hirsch FR, Skov T, Nielsen HW. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies. Histopathology. 1994 Nov; 25(5):431-7. PMID: 7868083.
      View in: PubMed
    286. Børch K, Jacobsen T, Olsen JH, Hirsch FR, Hertz H. [Neonatal cancer in Denmark 1943-1985]. Ugeskr Laeger. 1994 Jan 10; 156(2):176-9. PMID: 8296406.
      View in: PubMed
    287. Hirsch FR, Dombernowsky P, Hansen HH. Treatment of small cell lung cancer: the Copenhagen experience. Anticancer Res. 1994 Jan-Feb; 14(1B):317-9. PMID: 8166475.
      View in: PubMed
    288. Sørensen JB, Hirsch FR, Gazdar A, Olsen JE. Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer. 1993 May 15; 71(10):2971-6. PMID: 8387872.
      View in: PubMed
    289. Bobrow LG, Hirsch FR, Hay FG, Happerfield L, Skov BG, Law K, Leonard RC, Souhami RL. An immunohistochemical investigation of diagnostic biopsy material taken from short and long term survivors with small cell lung cancer. Br J Cancer. 1992 Sep; 66(3):547-51. PMID: 1325828; PMCID: PMC1977947.
    290. Hirsch FR, Osterlind K, Jensen LI, Thomsen C, Peters K, Jensen F, Hansen HH. The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer. Ann Oncol. 1992 Jun; 3(6):469-74. PMID: 1323323.
      View in: PubMed
    291. Skov BG, Hirsch FR, Bobrow L. Monoclonal antibodies in the detection of bone marrow metastases in small cell lung cancer. Br J Cancer. 1992 Apr; 65(4):593-6. PMID: 1373295; PMCID: PMC1977544.
    292. Skov BG, Hirsch FR, Hay FG, Olsen JE, Bobrow LG. Expression of 'small cell carcinoma antigens' in primary small cell lung cancer and metastases: an immunohistochemical study. Br J Cancer Suppl. 1991 Jun; 14:46-8. PMID: 1645571; PMCID: PMC2204103.
    293. Skov BG, Sørensen JB, Hirsch FR, Larsson LI, Hansen HH. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol. 1991 May; 2(5):355-60. PMID: 1954180.
      View in: PubMed
    294. Osterlind K, Hansen M, Hirsch FR, Dombernowsky P, Sörenson S, Pedersen AG, Hansen HH. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. Ann Oncol. 1991 Jan; 2(1):41-6. PMID: 1848996.
      View in: PubMed
    295. Jørgensen LG, Hirsch FR, Skov BG, Osterlind K, Cooper EH, Larsson LI. Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. Br J Cancer. 1991 Jan; 63(1):151-3. PMID: 1703432; PMCID: PMC1971651.
    296. Hirsch FR, Hansen HH. The clinical relevance of recent developments in pathology and biology of small cell lung cancer. Chest. 1989 Jul; 96(1 Suppl):34S-37S. PMID: 2544357.
      View in: PubMed
    297. Kristjansen PE, Hirsch FR. A review of the 5th World Conference on Lung Cancer held by the International Association for the Study of Lung Cancer. Eur Respir J. 1989 Mar; 2(3):275-9. PMID: 2543597.
      View in: PubMed
    298. Hirsch FR, Matthews MJ, Aisner S, Campobasso O, Elema JD, Gazdar AF, Mackay B, Nasiell M, Shimosato Y, Steele RH, et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer. 1988 Sep 01; 62(5):973-7. PMID: 2842029.
      View in: PubMed
    299. Sørensen JB, Hirsch FR, Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease. Cancer. 1988 Jul 15; 62(2):361-7. PMID: 3383137.
      View in: PubMed
    300. Hirsch FR. Small-cell lung cancer--the clinical relevance of the histopathological classification and some biological aspects. Chemioterapia. 1987 Jun; 6(2 Suppl):696-8. PMID: 2855619.
      View in: PubMed
    301. Hirsch FR, Osterlind K, Kristjansen PE, Hansen HH. Bone marrow examination in small cell lung cancer. Ann Intern Med. 1987 Jun; 106(6):913. PMID: 3034111.
      View in: PubMed
    302. Hirsch FR, Hansen HH, Hansen M, Osterlind K, Vindeløv LL, Dombernowsky P, Sørensson S. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol. 1987 Apr; 5(4):585-91. PMID: 3031225.
      View in: PubMed
    303. Elliott JA, Osterlind K, Hirsch FR, Hansen HH. Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. J Clin Oncol. 1987 Feb; 5(2):246-54. PMID: 3027269.
      View in: PubMed
    304. Sehested M, Hirsch FR, Osterlind K, Olsen JE. Morphologic variations of small cell lung cancer. A histopathologic study of pretreatment and posttreatment specimens in 104 patients. Cancer. 1986 Feb 15; 57(4):804-7. PMID: 3002587.
      View in: PubMed
    305. Hirsch FR, Osterlind K, Hansen HH. The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients. Cancer. 1983 Dec 01; 52(11):2144-50. PMID: 6313181.
      View in: PubMed
    306. Osterlind K, Sörenson S, Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, Rørth M. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res. 1983 Dec; 43(12 Pt 1):6085-9. PMID: 6315227.
      View in: PubMed
    307. Hage E, Hansen M, Hirsch FR. Electron microscopic sub-classification of small cell carcinoma of the lung. Acta Pathol Jpn. 1983 Jul; 33(4):671-81. PMID: 6312735.
      View in: PubMed
    308. Hirsch FR, Paulson OB, Hansen HH, Larsen SO. Intracranial metastases in small cell carcinoma of the lung. Prognostic aspects. Cancer. 1983 Feb 01; 51(3):529-33. PMID: 6295606.
      View in: PubMed
    309. Hirsch FR, Ottesen G, Pødenphant J, Olsen J. Tumor heterogeneity in lung cancer based on light microscopic features. A retrospective study of a consecutive series of 200 patients, treated surgically. Virchows Arch A Pathol Anat Histopathol. 1983; 402(2):147-53. PMID: 6320525.
      View in: PubMed
    310. Hirsch FR, Paulson OB, Hansen HH, Vraa-Jensen J. Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. Cancer. 1982 Dec 01; 50(11):2433-7. PMID: 6182974.
      View in: PubMed
    311. Hirsch FR, Matthews MJ, Yesner R. Histopathologic classification of small cell carcinoma of the lung: comments based on an interobserver examination. Cancer. 1982 Oct 01; 50(7):1360-6. PMID: 6286092.
      View in: PubMed
    312. Vindeløv LL, Hansen HH, Gersel A, Hirsch FR, Nissen NI. Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. Cancer Res. 1982 Jun; 42(6):2499-505. PMID: 6280861.
      View in: PubMed
    313. Sehested M, Hirsch FR, Hou-Jensen K. Immunoperoxidase staining for carcinoembryonic antigen in small cell carcinoma of the lung. Eur J Cancer Clin Oncol. 1981 Oct; 17(10):1125-31. PMID: 6279407.
      View in: PubMed
    314. Sehested M, Hirsch FR, Hou-Jensen K, Hansen HH. Histological examination for Z-gene alpha 1-antitrypsin deficiency in small cell anaplastic carcinoma of the lung. Eur J Respir Dis. 1981; 62(2):107-10. PMID: 6263662.
      View in: PubMed
    315. Vindeløv LL, Hansen HH, Christensen IJ, Spang-Thomsen M, Hirsch FR, Hansen M, Nissen NI. Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res. 1980 Nov; 40(11):4295-300. PMID: 6258777.
      View in: PubMed
    316. Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, Rygård J. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. Cancer. 1980 Jul 15; 46(2):279-84. PMID: 6992979.
      View in: PubMed
    317. Hirsch FR, Hansen HH. Bone marrow involvement in small cell anaplastic carcinoma of the lung: prognostic and therapeutic aspects. Cancer. 1980 Jul 01; 46(1):206-11. PMID: 7388761.
      View in: PubMed
    318. Hansen M, Hansen HH, Hirsch FR, Arends J, Christensen JD, Christensen JM, Hummer L, Kühl C. Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes. Cancer. 1980 Mar 15; 45(6):1432-7. PMID: 6244082.
      View in: PubMed
    319. Hirsch FR, Hansen HH, Hainau B. Bilateral bone-marrow examinations in small-cell anaplastic carcinoma of the lung. Acta Pathol Microbiol Scand A. 1979 Jan; 87(1):59-62. PMID: 217234.
      View in: PubMed
    320. Hansen HH, Dombernowsky P, Hirsch FR. Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma. Semin Oncol. 1978 Sep; 5(3):280-7. PMID: 211639.
      View in: PubMed
    Hirsch's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)